Hossein Borghaei, DO, MS, Fox Chase Cancer Center


Future Directions in Treatment of Small Cell Lung Cancer

August 26th 2021

Panelists conclude their discussion by commenting on areas of unmet need and sharing personal perspectives on factors that may change clinical practice for SCLC in the future.

Emerging Treatments in SCLC: Impact of Targeted Therapy

August 26th 2021

Key opinion leaders in lung cancer share personal thoughts on the potential for bispecific agents and the overall impact of inhibiting molecular targets.

Emerging Treatments in SCLC: Triplets + Limited-Stage Disease

August 19th 2021

Anne Chiang, MD, PhD, reviews the study design of 2 clinical trials, adding a third agent to the standard-of-care regimen of chemotherapy plus I/O; Stephen Liu, MD, discusses clinical trials in limited-stage disease.

Emerging Treatments in SCLC: Targeting DNA Damage

August 19th 2021

Thoracic oncology expert Vivek Subbiah, MD, provides an overview of recent clinical trials studying agents targeting DNA damage for the treatment of small cell lung cancer.

Future Directions in ES SCLC

July 29th 2021

Panelists reflect on treatment considerations for asymptomatic brain metastases, progress in biomarker research, and frequency of administering checkpoint inhibitors.

Treatment Considerations: Chemotherapy + IO in ES SCLC

July 22nd 2021

Panelists reflect on key points from recent studies in ES SCLC by discussing patients for whom immunotherapy may be appropriate, examining the role of adding CTLA4 inhibition to a PD-L1 inhibitor, and reviewing factors to consider when deciding between cisplatin or carboplatin.

First-Line Therapy in ES SCLC: CASPIAN

July 15th 2021

Thoracic oncologist, Anne Chiang, MD, PhD, reviews the trial design and results of the CASPIAN trial and emphasizes implications for long-term benefit of combining platinum chemotherapy with durvalumab.

First-Line Therapy in ES SCLC: IMpower133

July 15th 2021

Stephen Liu, MD guides a discussion on recent updates on IO+chemotherapy combinations in extensive-stage small cell lung cancer by reviewing data from the phase 3 IMpower133 l trial of carboplatin/etoposide/atezolizumab.